Tag archive for ‘Curis Inc.’
Initial Report (CRIS, $1.92)
Summary and Overview Curis has demonstrated impressive drug development capability in the oncology space. However, it has followed a policy of licensing drugs early in development and passing development costs and risks on to the licensor. This de-risked the drug development for Curis, but at the cost of giving up significant economics. For example, its […]